Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze XERS stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate XERS investment potential.

What is XERS stock price today?

Get real-time XERS stock price, historical data, and price charts on Financhill. Track XERS performance with our advanced analysis tools.

Is XERS a good investment?

Evaluate XERS investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy XERS stock?

To buy XERS stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of XERS?

View detailed market capitalization data and company valuation metrics for XERS on our comprehensive analysis page.

What is the P/E ratio of XERS?

Use our fundamental analysis tools to view XERS P/E ratio and compare valuation metrics with industry peers.

What are XERS earnings?

View XERS earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Xeris Biopharma Holdings, Inc. 10K Form

Buy

XERS
Xeris Biopharma Holdings, Inc.

Last Price:

$6.72

Seasonality Move:

1.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-10	10Q	XERS/Xeris Biopharma Holdings, Inc. Quarterly
2020-05-07	10Q	XERS/Xeris Biopharma Holdings, Inc. Quarterly
2020-03-12	10K	XERS/Xeris Biopharma Holdings, Inc. Annual
2019-11-07	10Q	XERS/Xeris Biopharma Holdings, Inc. Quarterly
2019-08-06	10Q	XERS/Xeris Biopharma Holdings, Inc. Quarterly
2019-05-09	10Q	XERS/Xeris Biopharma Holdings, Inc. Quarterly

Receive XERS News And Ratings

See the #1 stock for the next 7 days that we like better than XERS

XERS Financial Statistics

Sales & Book Value

Annual Sales:	$203.1M
Cash Flow:	$18.4M
Price / Cash Flow:	107.56
Annual Sales:	$-0.01
Price / Book:	0

Profitability

EPS (TTM):	-0.10340
Net Income (TTM):	$-15.6M
Gross Margin:	$155.4M
Return on Equity:	-1019.2%
Return on Assets:	-4.68%

Xeris Biopharma Holdings, Inc. Earnings Forecast

Key Xeris Biopharma Holdings, Inc. Financial Ratios

The Gross Profit Margin over the past 9 years for XERS is 76.52%.
The Selling, General & Administrative Expenses for XERS have been equal to 80.50% of Gross Profit Margin.
The Research & Development expenses have been 12.59% of Revenue.
The Net Earning history of XERS is -27.00% of Total Revenues.
Per Share Earnings over the last 9 years have been positive in 7 years.

Xeris Biopharma Holdings, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Pharmaceuticals
Sector:	Health Care
Current Symbol:	XERS
CUSIP:	98422L
Website:	xerispharma.com

Debt

Debt-to-Equity Ratio:	-299.25
Current Ratio:	1.93
Quick Ratio:	1.25

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	22.03

XERS Technical Analysis vs Fundamental Analysis

Buy

Xeris Biopharma Holdings, Inc. (XERS) is a Buy

Is Xeris Biopharma Holdings, Inc. a Buy or a Sell?

Xeris Biopharma Holdings, Inc. stock is rated a Buy

The current Xeris Biopharma Holdings, Inc. [XERS] share price is $6.72. The Score for XERS is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.